Evaluation of a Multiplexed Immunoassay for Assessing Long-Term Humoral Immunity to Monkeypox virus infection and Orthopoxvirus Vaccination

3

4 Bethany Hicks^{1*}, Scott Jones¹, Helen Callaby^{2,8}, Daniel Bailey², Claire Gordon², Tommy Rampling², Catherine

- 5 Houlihan², Ezra Linley⁷, Simon Tonge⁷, Clarissa Oeser⁶, Rachael Jones³, Marcus Pond⁴, Ravi Mehta⁴, Deborah
- 6 Wright⁵, Bassam Hallis¹, Cathy Rowe¹, Ashley Otter¹
- 7
- 8 ¹Emerging Pathogen Serology Group, Vaccine Development Evaluation and Preparedness Centre, UK Health
- 9 Security Agency, Porton Down, Wiltshire, UK
- 10 ²Rare and Imported Pathogens Laboratory, UK Health Security Agency, Porton Down, Wiltshire, UK
- 11 ³Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
- 12 ⁴Imperial College Healthcare NHS Trust, London, UK
- 13 ⁵Research and Development, UK Health Security Agency, Porton Down, Wiltshire, UK
- ⁶Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, Colindale, London, UK
- 15 ⁷Seroepidemiology Unit, UK Health Security Agency, Manchester, UK
- 16 ⁸The Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
- 17
- 18 *Corresponding author: bethany.hicks@ukhsa.gov.uk

19 Abstract

20 In the summer of 2022, a large outbreak of Monkeypox virus (MPXV) cases occurred globally. 21 By December 2022, a total of 3,582 Mpox cases had been confirmed within the UK. As a 22 result, the Modified Vaccinia Ankara-Bavarian Nordic ("IMVANEX") vaccine was offered to 23 high-risk groups to protect against the spread of the virus. This outbreak led to the 24 development of multiple serological assays to aid the current understanding of Mpox 25 immunology. This study assessed the performance of a multiplexed solid-phase 26 electrochemiluminescence (Meso Scale Discovery (MSD)) immunoassay for simultaneous 27 detection of antibodies against MPXV A29, A35, B6, E8, and M1 antigens, along with the 28 corresponding Vaccina Virus (VACV) homologues A27, A33, B5, D8, and L1. Sensitivity and 29 specificity were evaluated with paediatric negatives (n=215), pre- and post-IMVANEX 30 vaccinated (n=80) and MPXV (2022 Clade IIb outbreak, n=39) infected serum samples. The 31 overall Orthopoxvirus multiplex assay demonstrated high specificity ranging from 75.68% (CI: 32 69.01-81.29) - 95.98% (CI:92.54-97.87) and sensitivity from 62.11% (CI:52.06-71.21) -33 98.59% (CI:92.44% - 99.93%) depending on the Orthopoxvirus antigen, either used singularly 34 or combined. Additionally, preferential binding was observed between Mpox-infected individuals and MPXV antigens, whilst vaccinated individuals exhibited increased binding to 35 36 VACV antigens. These results highlight the differential binding patterns between antigen 37 homologues in closely related viruses. Using this assay, we show that the Orthopoxyirus MSD 38 assay is highly sensitive in detecting IgG titres for vaccinated sera ≥24-days post dose one 39 and ≥14-days post dose two for all antigens within the assay except for MPXV A29 and VACV 40 A27. A similar trend was observed with convalescent sera, although differing antigens 41 demonstrate stronger sensitivities. Overall, this assay has the capability to accurately assess 42 antibody titres for multiple relevant MPXV and VACV antigens post infection and post 43 vaccination, demonstrating its utility in understanding immune responses to Orthopox viruses 44 in current and future outbreaks, and assessing the immunogenicity of new generation 45 Orthopox and Mpox-specific vaccinations. 46

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

47 Introduction

48 MPXV is a zoonotic Orthopoxvirus (OPXV) characterised as a large dsDNA virus with 49 a genome encoding over 200 different proteins¹. This complex antigenic profile poses 50 challenges with serological discrimination due to increased cross-reactivity of surface 51 proteins. Furthermore, MPXV has two closely related clades; Clade I (formerly Congo 52 Basin), and Clade II (formerly West African)², whereby Clade IIb was the primary clade 53 in the recent 2022 Mpox outbreak in various non-endemic countries^{3–5}.

54

Vaccinia virus $(VACV)^{6,7}$ has been essential in the development of various licensed smallpox vaccines⁸, which was successfully implemented to eradicate smallpox in the 1980s⁹. This eradication was possible due to the immunogenicity of VACV and its ability to provide cross-protection against additional Orthopoxviruses including Monkeypox Virus (MPXV), Cowpox virus (CPXV) and Variola virus (VARV)¹⁰. During the 2022 Mpox outbreak it was estimated that the efficacy of one IMVANEX vaccination dose against MPXV is \geq 78%^{11–14}.

62

It has been demonstrated that the recent second and third-generation Smallpox 63 vaccines (ACAM2000 and IMVANEX, respectively) produce a similar antigenic 64 response to MPXV infection¹⁵. This parallel immune response allows antibodies to 65 bind to numerous MPXV and VACV antigens due to the high sequence homology in 66 these proteins. Likewise, OPXV-elicited antibodies have increased cross-neutralising 67 capability than other virus families¹⁶, although the research on discriminatory antigens 68 69 and post-infection or vaccination immunity specific to MPXV antigens remain limited 70 15,17,18

71 Surface proteins between VACV and MPXV-2022 exhibit approximately 94-98% sequence similarity¹⁷. During inter-host transmission, the mature virion is dominant 72 73 where ~25 membrane proteins are expressed, including MPXV A29 and E8 with VACV 74 homologues A27 and D8 with an additional six proteins on the envelope (including 75 MPXV A35 and M1)¹⁸ that play a dominant role in the intra-host transmission¹⁹. Due 76 to the diverse number of immunodominant antigens, this initiated an increase in assay 77 development by diverse groups and manufacturers to enable investigation of trends in 78 serosurveillance, identification of MPXV cases, and evaluation of vaccine antibody waning necessitating booster doses^{15,20,21}. However, many assays remain limited to 79

80 single-plex, restricting the simultaneous evaluation of multiple antigens in a single well. 81 Recognised for its high sensitivity multiplex capabilities, Meso Scale Discovery (MSD) 82 developed an Orthopoxvirus assay that measures IgG antibody responses to five 83 MPXV and five VACV immunodominant antigens. These range from cell adhesion 84 through either binding chondroitin sulphate (MPXV E8 and VACV D8)²² or heparan sulphate (MPXV A29 and VACV A27)23,24, whereas MPXV B5 and VACV B6 are 85 86 Extracellular Envelope virus (EEV)²⁵ which have been identified to be a target for EEVneutralising antibodies²⁶. 87

88

A multiplex assay such as the Orthopoxvirus MSD panel described here enables
higher-throughput screening of samples for quantifying antigen-specific antibodies.
However, with next-generation Smallpox or Mpox-specific vaccines such as mRNA²⁷,
there is a need for more discrete immunology assays than using MVA or whole-virus
serology assays. Here, we demonstrate the sensitivity and specificity of the MSD
Orthopoxvirus assay that simultaneously measures IgG to five MPXV (A29, A35, B6,
E8 and M1) and five VACV antigens (A27, A33, B5, D8 and L1).

96 Materials and Methods

97 Sample collection

98 Serum samples

Sera were obtained from individuals with an IMVANEX vaccination (n= 9 post-dose 1 99 100 (PD1), n=65 post dose 2 (PD2)), recruited from UKHSA Porton Down. Individuals were 101 bled 24 days after dose one, then 14 days after dose two followed by approximate 102 monthly bleeds up to 220 days after dose two. Anonymised Mpox convalescent serum 103 (n=39) was obtained from PCR-confirmed infection from the 2022 outbreak (Clade IIb) 104 from the Rare and Imported Pathogens Laboratory, Imperial College Healthcare NHS 105 Trust and Chelsea and Westminster Hospital NHS Foundation Trust. To determine the 106 assays specificity paediatric samples (n=215) from the UK Health Security Agency 107 (UKHSA) Seroepidemiology Unit (SEU) were sourced as negative samples.

108 Meso Scale Discovery (MSD) IgG Electrochemiluminescence immunoassay 109 (ECLIA)

110 The MesoScale Discovery V-PLEX Orthopoxvirus Panel 1 (K15688U-2) 111 electrochemiluminescence immunoassay (ECLIA) (MSD, Rockville, MD) was used to 112 specifically measure IgG antibody binding to five MPXV (A29L, A35R, B6R, E8L and 113 M1R) and five VACV (A27L, A33R, B5R, D8L and L1R) antigens in parallel in a 96-114 well 10 spot plate format. MSD assays were performed as per the manufacturer's 115 instructions. Briefly, 96-well plates were blocked with MSD Blocker A, following plate 116 washing three times with 300 µl/well of PBS with Tween20 (0.01% final) using a Biotek 117 405 TS plate washer. Serum samples were diluted 1:1,000-10,000 in the 118 manufacturers diluent buffer before being added to the MSD plate, along with the 119 assay reference standard and controls. After incubation and a washing step, the 120 detection antibody (MSD SULFO-TAG[™] Anti-Human IgG Antibody) was added to 121 each well. After further incubation and washing, MSD GOLD Read Buffer B was 122 added, and plates read using the MESO QuickPlex[™] SQ 120. A standard curve was 123 established by fitting the signals from the standard using a 4-parameter logistic model. 124 Concentrations of samples were determined from the electrochemiluminescence 125 signals by back-fitting to the standard curve and multiplying by the dilution factor. 126 Antibody concentrations are expressed in Arbitrary Units/ml (AU/ml). Kits were

- 127 provided by MSD for evaluation purposes, with no involvement in the study design,
- 128 result interpretation, or manuscript writing.

129 Statistical analysis

- 130 Data analysis was performed using MSD Discovery Workbench 4.0 and GraphPad
- 131 Prism version 9.2.0 (GraphPad, San Diego, CA).

132 Ethics

- 133 IMVANEX Smallpox-vaccinated samples were obtained from individuals with written
- 134 consent through UKHSA Research and Ethics Committee for assay validation. Mpox
- 135 PCR-confirmed cases were granted approval for assay performance validation by the
- 136 NHS Research Ethics Committee (reference 22/HRA/3321) as described by Otter et
- 137 *al.*, 2023¹⁵.

138 Results

Evaluation of assay sensitivity and specificity for Orthopox vaccine and MPXV serology


Receiver operator curves (ROC) were plotted to determine the sensitivity and 141 142 specificity using negatives against Mpox-infected and IMVANEX vaccinated samples 143 for each antigen (**Table 1** and **Figure 1**). In addition to determine the area under the 144 curve (AUC) to measure the accuracy of individual antigens. The AUC values were 145 calculated based on the performance of the antigens in discriminating between 146 negative and infected or vaccinated. Highest AUC values were observed for MPXV 147 B6, MPXV E8, VACV A33, VACV B5 and VACV D8, with an AUC comparable for all 148 antigens with a range of 0.76-0.99. **Table 1** indicates the positive/negative cut-offs for 149 each antigen determined from the ROC analysis using a likelihood ratio (LR) 150 calculation. MPXV A29 (62.11% (CI:52.06-71.21)) and its homologue VACV A27 151 (65.52% (CI:56.50-73.54)) were found to have much lower specificity and sensitivity 152 compared to the other antigens when comparing negative samples with vaccinated 153 and/or infected.

154

155 We next sought to assess ROC curves and therefore sensitivity and specificity for 156 individual cohorts, separating vaccinated (IMVANEX dose 1 and 2 vaccinated) and 157 MPXV convalescent sera (Supplementary Table 1A & B). Whilst specificity and 158 sensitivity remained consistent across most antigens, MPXV A29 and VACV A27, 159 showed higher sensitivity for MPXV convalescent sera in contrast to IMVANEX 160 vaccinated sera sensitivity: 88.89% (CI:74.69-95.59) and 57.69% (CI:46.62-68.04), 161 specificity: 90.09% (CI:85.45-93.36) and 69.82% (CI:63.49-75.48), respectively (Table 162 1, Figure 1A).

163

164 Conversely, MPXV M1 and VACV L1 demonstrated stronger sensitivity in detecting 165 antibody responses in IMVANEX vaccinated sera compared to Mpox-infected sera, 166 with a sensitivity of 91.30% (CI:82.30-95.95) and 81.58% (CI:66.58-90.78), and 167 specificity: 84.82% (CI:79.54-88.93) and 77.23% (CI:71.31-82.24), respectfully 168 (**Figure 1E, Table 1**).



170 Figure 1: Receiver Operating Curves (ROC) for MPXV and VACV antigens, using negative samples as controls against 171 positive samples as either post-Mpox infected ("Infection") and/or post-IMVANEX vaccination ("IMVANEX"). ROC curves 172 demonstrating the sensitivity versus 100%-specificity of MPXV antigens with post-vaccination (Blue) or post-infection (Black) and 173 corresponding homologous VACV antigen with post-vaccination (Red) or post-infection (Green). Each homologous antigen pair from 174 the MSD assay are included: (A) MPXV A29 and VACV A27, (B) MPXV A35 and VACV A33, (C) MPXV B5 and VACV B6, (D) MPXV 175 E8 and VACV D8, and (E) MPXV M1 and VACV L1. Each solid line represents the ROC curve for the individual antigens and the 176 dotted red line represents the random classifier. Negative samples (n=215) were compared against post Mpox-infection (n=39) and 177 post IMVANEX vaccination samples (n=80).

178 Table 1: Comparative analysis of sensitivity and specificity for multiple MPXV

and VACV antigens using ROC analysis. Sensitivity, specificity, and area under the

180 curve (AUC) are stated for each individual antigen, as well as all 10 antigens combined

181 based on the positivity score. Using paediatric negative (n=215) as controls, post

182 Mpox-infection (n=39) and post IMVANEX vaccination (n=80) were compared.

183 184

Cut-off	Sensitivity %	95% CI	Specificity %	95% CI	Likelihood Ratio	AUC
> 2.358	62.11	52.06% to 71.21%	82.43	76.89% to 86.87%	3.54	0.784
> 2.112	65.52	56.50% to 73.54%	75.68	69.01% to 81.29%	2.69	0.757
> 2.752	91.60	85.22% to 95.37%	90.63	86.09% to 93.79%	9.77	0.969
> 6.349	93.28	87.29% to 96.55%	95.54	91.98% to 97.56%	20.89	0.985
> 2.666	94.12	88.35% to 97.12%	95.52	91.94% to 97.55%	20.99	0.989
> 6.151	95.61	90.14% to 98.11%	95.52	91.94% to 97.55%	21.32	0.987
> 22.20	98.59	92.44% to 99.93%	95.98	92.54% to 97.87%	24.54	0.989
> 25.99	96.25	89.55% to 98.98%	97.77	94.88% to 99.04%	43.12	0.988
> 11.19	83.90	76.22% to 89.44%	84.82	79.54% to 88.93%	5.53	0.913
> 10.37	85.83	78.48% to 90.96%	83.93	78.55% to 88.16%	5.34	0.924
> 4.50	92.92	86.65 % to 96.37%	93.98	89.98% to 96.45%	15.44	0.970
	 > 2.358 > 2.112 > 2.752 > 6.349 > 2.666 > 6.151 > 22.20 > 25.99 > 11.19 > 10.37 	% > 2.358 62.11 > 2.112 65.52 > 2.752 91.60 > 6.349 93.28 > 2.666 94.12 > 6.151 95.61 > 22.20 98.59 > 25.99 96.25 > 11.19 83.90 > 10.37 85.83	% 52.06% to 71.21% > 2.358 62.11 52.06% to 71.21% > 2.112 65.52 56.50% to 73.54% > 2.752 91.60 85.22% to 95.37% > 6.349 93.28 87.29% to 96.55% > 2.666 94.12 88.35% to 97.12% > 6.151 95.61 90.14% to 98.11% > 22.20 98.59 92.44% to 99.93% > 25.99 96.25 89.55% to 98.98% > 11.19 83.90 76.22% to 89.44% > 10.37 85.83 78.48% to 90.96%	% % > 2.358 62.11 52.06% to 71.21% 82.43 > 2.112 65.52 56.50% to 73.54% 75.68 > 2.752 91.60 85.22% to 95.37% 90.63 > 6.349 93.28 87.29% to 96.55% 95.54 > 2.666 94.12 88.35% to 97.12% 95.52 > 6.151 95.61 90.14% to 98.11% 95.52 > 22.20 98.59 92.44% to 99.93% 95.98 > 25.99 96.25 89.55% to 98.98% 97.77 > 11.19 83.90 76.22% to 89.44% 84.82 > 10.37 85.83 78.48% to 90.96% 83.93	% % > 2.358 62.11 52.06% to 71.21% 82.43 76.89% to 86.87% > 2.112 65.52 56.50% to 73.54% 75.68 69.01% to 81.29% > 2.752 91.60 85.22% to 95.37% 90.63 86.09% to 93.79% > 6.349 93.28 87.29% to 96.55% 95.54 91.98% to 97.56% > 2.666 94.12 88.35% to 97.12% 95.52 91.94% to 97.55% > 2.666 94.12 88.35% to 98.11% 95.52 91.94% to 97.55% > 2.220 98.59 92.44% to 99.93% 95.98 92.54% to 97.87% > 22.99 96.25 89.55% to 98.98% 97.77 94.88% to 99.04% > 11.19 83.90 76.22% to 89.44% 84.82 79.54% to 88.93% > 10.37 85.83 78.48% to 90.96% 83.93 78.55% to 88.16%	%%Ratio> 2.35862.1152.06% to 71.21%82.4376.89% to 86.87%3.54> 2.11265.5256.50% to 73.54%75.6869.01% to 81.29%2.69> 2.75291.6085.22% to 95.37%90.6386.09% to 93.79%9.77> 6.34993.2887.29% to 96.55%95.5491.98% to 97.56%20.89> 2.66694.1288.35% to 97.12%95.5291.94% to 97.55%20.99> 6.15195.6190.14% to 98.11%95.5291.94% to 97.55%21.32> 22.2098.5992.44% to 99.93%95.9892.54% to 97.87%24.54> 25.9996.2589.55% to 98.98%97.7794.88% to 99.04%43.12> 11.1983.9076.22% to 89.44%84.8279.54% to 88.93%5.53> 10.3785.8378.48% to 90.96%83.9378.55% to 88.16%5.34

186 Utilising multiple antigens to determine Orthopox-positivity

187 As a multi-antigen assay, we sought to determine the ability to classify samples as 188 positive based on the results to multiple antigens. Using the previously calculated cut-189 off values for each antigen (Table 1), we applied these to a panel of positive 190 (vaccinated or infected) and negative samples, categorising samples as positive if they 191 were greater than the respective cut-off values for each antigen. If a sample was above 192 the cut off for each antigen, a value of one was assigned to it. The positivity count for 193 each sample was assessed on a scale out of ten due to the 10 antigens. Using ROC 194 analysis on negative versus positive samples, samples positive on 5 antigens resulted 195 in a sensitivity of 92.92% (CI:86.65-96.37) and specificity of 93.98% (CI:89.98-96.45) 196 (**Table 1**). Samples positive on greater than or equal to five antigens did not show an 197 improvement in sensitivity or specificity, whilst less than five resulted in both decreases 198 in sensitivity and specificity (Supplementary Figure 2A). This aligns with the observed trends in AUC values among IMVANEX-vaccinated and/or Mpox-infected 199 200 individuals. For instance, the AUC ranges vary slightly across different cohorts, with 201 values ranging from 0.734-0.944 for IMVANEX-vaccinated, 0.946-0.963 for Mpox-202 infected, and 0.807-0.950 for both cohorts combined. Notably, samples positive to five 203 or more antigens consistently exhibit increased AUC values, reaching an equilibrium 204 at approximately 0.97 (Supplementary Figure 2A).

205 Comparative analysis of antibody titres to MPXV and VAVC antigens across 206 cohorts

207 The evaluation of antibody titres across various cohorts revealed evident patterns for 208 different antigens. Negative samples from paediatric samples predominantly 209 demonstrated median antibody titres below the corresponding cut-off values 210 (Supplementary Table 2). Most notably, the paediatric negative samples exhibited 211 significantly (p<0.00001) lower antibody titres for all antigens except MPXV A29, A35. 212 B6 and VACV B5 (Figure 2). Post-dose 1 (PD1) median antibody titres for all antigens 213 were generally all positive; however, for MPXV A29, VACV A27, and MPXV A35, a 214 number of results were borderline with the identified cut-off value for individual 215 antigens (negative vs vaccination and Mpox-infected sera). Additionally, 14 days post-216 dose two (PD2) and further subsequent time points up to 84 days post dose two, 217 significant increase in antibody levels was evident, displaying statistically significant 218 (p<0.00001) differences from negatives for all antigens within the assay; MPXV A35, 219 B6, E8, M1 and VACV A27 (p<0.0001), A33, B5, D8 and L1 (Figure 2).

220

221 Sera from vaccinated individuals were found to contain minimal antibodies directed 222 towards MPXV A29 and VACV A27 antigens, with low levels of positivity and only 56% 223 of positive samples exhibiting titres above the assigned cut-off value compared to 224 other antigens, such as MPXV E8 and VACV D8 in which 100% of positive samples 225 (vaccinated or infected) were found to be above the cut-off. Notably, positivity above 226 the cut-off decreased from 63 days (PD2.3) and 122 days (PD2.5) post-second dose 227 for MPXV A29 and VACV A27, with 0% positivity 157 days (PD2.6) and 185 days 228 (PD2.7) post-second dose for MPXV A29 and for VACV A27, respectfully.

229

Conversely, 95% of Mpox-infected individuals are above the cut-off for MPXV A29 and
VACV A27, with median antibody titres for these antigens at 96.07 AU/ml (CI:51.27234.70) for MPXV A29 and 64.52 AU/ml (CI:32.15-145.50) for VACV A27. Compared
to the average of all post-vaccination median values targeting these antigens, were
markedly lower at 1.05 AU/ml (CI:0.60-2.04) and 2.02 AU/ml (CI:0.91-3.38),
respectively (Supplementary Table 2).


- 236
- 237
- 238

239 Analysis of serological reactivity to homologous MPXV/VACV proteins

240 In a comparative analysis of protein homologues, we demonstrate a notable trend in 241 preferential binding between MPXV/VACV homologues (Figure 3). We observed that 242 sera from IMVANEX vaccinated individuals demonstrated preferential binding to 243 VACV A33, B5 and D8, compared to the corresponding MPXV homologues A35, B6 244 and D8. Furthermore, we reveal contrasting antibody responses among MPXV 245 convalescent sera compared to vaccine-induced sera. Mpox-infected individuals 246 exhibit a stronger antibody response to MPXV A29 compared to its antigen homologue 247 VACV A27 (Figure 3A). Mpox convalescent sera showed higher antibody levels 248 (AU/ml) against MPXV A29 and VACV A27, with a majority (94%) of samples positive 249 above the cut-off. Conversely, sera from vaccinated individuals demonstrated lower 250 antibody responses, with over half (56%) of results falling below the corresponding 251 cut-offs for these antigens (Table 1), parallel with the observations in Figure 3A.

252

253 Conversely, MPXV M1 and VACV L1 antigens showed a reverse trend whereby 254 IMVANEX-vaccinated individuals demonstrated preferential binding to VACV L1 rather 255 than MPXV M1. Specifically, antibody positivity levels among Mpox-infected 256 individuals were lower and border the cut-off value (24.64 AU/ml for MPXV M1 and 257 19.57 AU/ml for VACV L1, **Supplementary Table 2**). In contrast, vaccination-induced 258 antibody responses post dose two displayed >90% positivity above the cut-off, with slightly lower positivity post dose one (78% and 89% against MPXV M1 and VACV L1, 259 260 respectfully). Whereas Mpox-infected sera which exhibited antibody levels clustering 261 around the cut-off, with 30% of samples falling below the threshold.



265

266

Figure 2: Antigen specific analysis of antibody titres across various cohorts including negative, IMVANEX vaccinated and Mpox-22 infected individuals. Statistical significance was determined between positive cohorts against paediatric negatives (black asterisk) or against post dose one (PD1) (red asterisk) using an unpaired T test where *p < 0.05, **p < 0.001, ***p < 0.0001, and ****p < 0.00001. The cut-off value for each antigen is represented by the dashed line. (A) MPXV A29, (B) MPXV A35, (C) MPXV B6, (D) MPXV E8, (E) MPXV M1, (F) VACV A27, (G) VACV A33, (H) VACV B5, (I) VACV D8 and (J) VACV L1.









Figure 3: Correlation of post IMVANEX and MPXV convalescent sera to MPXV and VACV protein homologues: A) VACV A27 and MPXV A29 B) VACV A33 and MPXV A35 C) VACV B5 and MPXV B6 D) VACV D8 and MPXV E8 and E) VACV L1 and MPXV M1. The black dashed line response the corresponding cut-off for each antigen.

281 Correlation between MXPV and VACV antigens

282 Using Pearson correlation, we wanted to determine how antibody binding results for 283 each sample compare to one another for each VACV and MPXV antigen across Mpox-284 infected and IMVANEX vaccinated individuals. We observe that homologous proteins 285 MPXV E8/VACV D8 and MPXV M1/VACV L1 showed the strongest correlation 286 (Figure 4, Supplementary Table 3). In addition to the correlation observed between 287 the homologous proteins, we observed that some antigens were strongly correlated to one another. In particular, MPXV A35/VACV A33 strongly correlated with VACV 288 289 B5/MPXV B6, whilst VACV L1/MPXV M1 correlated to VACV A33, VACV D8/MPXV 290 E8, and VACV B5/MPXV B6.



310 Discussion

In response to the global Mpox outbreak in 2022, a number of assays have been developed to assess both immune responses to MPXV infection and Smallpox vaccination^{20,28}. Accurate assays for detecting MPXV and VAVC antibodies are critical for evaluating new vaccinations and for conducting serosurveillance studies to determine exposure to MPXV and those previously vaccinated, especially with ongoing Mpox infections in Europe, America and Asia, in addition to high-incidence countries such as DRC and Nigeria²⁹.

318

319 This study aimed to evaluate the sensitivity and specificity of the MSD Orthopoxvirus 320 10-plex assay, coated with immunodominant antigens MPXV M1, A35, B6 and A29 321 which have previously been identified to be highly immunogenic^{21,30–32}. We applied 322 this assay for the subsequent analysis of antibody titres across both infected and 323 IMVANEX ("JYNNEOS") vaccination cohorts to provide an understanding of the 324 humoral immune responses to both MPXV and VACV antigens. We have 325 demonstrated this assay exhibits a high level of specificity and sensitivity in detecting 326 antibodies against MPXV and VACV antigens, revealing antigen specific immune 327 responses post infection and/or vaccination.

328

329 Orthopoxvirus MSD panel demonstrates high sensitivity and specificity in 330 detecting Orthopoxvirus antibodies

Individual median fluorescence intensity (MFI) cut-offs were determined for each antigen using ROC analysis by comparing negatives against IMVANEX vaccinated and Mpox-infected (**Supplementary Figure 1**). The sensitivity and specificity varied across the ten antigens, with corresponding area under the curves (AUCs) ranging 335 from 0.757 (VACV A27) to 0.989 (MPXV E8). Certain antigens, such as MPXV A35, 336 B6 and E8, as well as VACV A33, B5 and D8, demonstrated high accuracy levels 337 (AUC values >0.96). This indicates the potential for these antigens in distinguishing 338 between vaccinated and/or Mpox-infected individuals to negative individuals. 339 However, when separating positive samples to either post Mpox-infected or post 340 IMMVANEX vaccinated, it was evident specific antigens (MPXV A29, M1 and VACV 341 A27 and L1) have differences in sensitivity and specificity values (Figure 1). While 342 both MPXV M1 and VACV L1 exhibit AUC values >0.9, there is a small discrepancy 343 between post IMVANEX vaccination and post Mpox-infection towards the sensitivity 344 and specificity for these antigens. An ROC analysis evaluating paediatric negatives to 345 vaccinated sera reveals a higher sensitivity (91.3 % CI:82.30-95.95) compared to 346 those infected with Mpox (81% CI:66.58-90.78) and vaccinated and Mpox-infected 347 individuals combined (83.9% CI:76.22-89.44) (Table 1, Supplementary Table 1). 348 This demonstrates that individuals vaccinated with IMVANEX generate a higher M1 349 antibody response compared to those infected, consistent with findings from previous studies²⁸. Additionally, it has been observed that mRNA vaccines (VGPox1 and 350 351 VGPox2, both encoding a fusion protein containing A35R and M1R) induce a rapid 352 and robust production of MPXV M1 and A35 specific antibodies seven days after 353 vaccination, indicating a more effective immune response to MPXV M1 compared to 354 natural infection which induced humoral immunity against other antigens with non-355 significant levels of M1-specific antibodies seven days post exposure³³.

356

357 Similarly, MPXV A29 and VACV A27 demonstrated lower specificity and sensitivity, 358 emphasising potential limitations in distinguishing between positive and negative 359 samples for these antigens, although they had AUCs of 0.78 and 0.76, respectively,

indicating adequate accuracy. Likewise, Yates et al.20 demonstrated that during the 360 361 development of a serological assay MPXV antigen A29 and its homologue VACV A27 362 had a low sensitivity and specificity with the AUC < 0.80, which showed similarities with 363 the antigens in this multiplexed assay. Interestingly, with vaccinated samples removed 364 from the ROC analysis, this increases the specificity (89% (CI:74.69-95.59)) and 365 specificity (90% (CI:85.45-93.36)), and likewise for VACV A27 sensitivity (84% 366 (CI:78.39-88.86)) and specificity (88.89% (CL:74.69%-95.59)) increases (Figure 1A). 367 This suggests there could be variation in the immune response between convalescent 368 individuals and those who received the IMVANEX vaccination for this antigen. It has 369 been identified that MPXV A29 is the main antigen used in immunoassays for MPXV 370 due to its location on the envelope³⁴, this suggests that individuals infected with MPXV 371 would likely generate a higher antibody response to MPXV A29 compared to those 372 vaccinated, as seen in this assay (Figure 2A). Likewise, MPXV A29 (along with 373 additional MPXV proteins A35, M1 and B6) have been identified to generate a CD4+ 374 T cell cellular response and are one of the primary targets of neutralising 375 antibodies^{21,35}.

376

377 Determining optimal assay cut-offs for detecting broad and specific 378 Orthopoxvirus antibodies

This assay shows that samples positive to 1 - 4 antigens have a lower specificity and sensitivity compared to \geq 5 antigens (**Supplementary Figure 2A**). The cut-off of \geq 5 antigens demonstrate a high sensitivity (93% CI:86.65-96.37) and specificity (94% CI:89.98-96.45), whilst evaluating different cohorts (convalescent versus vaccinated) to assess if an individual is positive to Orthopox antibodies. Whilst a limited number of commercial assays exist for Mpox serology, the MSD multiplex assays offers a unique

385 opportunity to assess antibody titres to individual antigens but also through our 386 classification method described here can be used for inferring the Orthopox-specific 387 immune status. With the established assay cut-off, this can be used to classify 388 individuals as positive or negative for Orthopoxvirus antibodies should they be above 389 the identified cut off for ≥5 antigens. This established assay offers a promising tool for 390 both diagnostic and serosurveillance applications, thereby enhancing further 391 serological research around Mpox in an easy-to-use format. A number of additional 392 antigens could be included in future assay developments, such as MPXV A27 which 393 have been shown to be differential for vaccinated from infected^{15,36}.

394

395 **Orthopoxvirus-specific IgG antibody dynamics vary by antigen**

396 Across the MPXV/VACV antigens we observe that Smallpox-vaccination (IMVANEX) 397 induces a similar antibody response to those infected with MPXV Clade IIb. Due to 398 their cross protection (as well as high genetic and antigenic homology), Smallpox 399 vaccines have been used to prevent and reduce the severity of Mpox¹³. Although 400 currently the Orthopoxvirus MSD plates are limited to five antigen homologues, future 401 generations of Orthopoxvirus vaccines are likely to be antigen specific as with the 402 development of a number of multivalent mRNA vaccines^{27,37}, highlighting the necessity 403 for multiplex assays for Orthopoxvirus immunity testing.

404

Whilst the Mpox genome has >200 proteins, the MSD assay is limited to 10 antigens in total (five of each MPXV and VACV homologous proteins), therefore other antigens capable of generating an immune response could be undetected in this assay. For instance, we previously demonstrated MPXV A27 as a potential discriminatory antigen between infected and vaccinated individuals due the truncation of the A27L gene in 410 MVA-BN (IMVANEX)¹⁵. In addition, we demonstrated MPXV B2 as a primary 411 immunodominant antigen after one IMVANEX dose¹⁵. The inclusion of additional 412 antigens such as these in newer generation serological assays are paramount to 413 antigens involved in protective identifying immune responses against 414 Orthopoxviruses, as well as discriminating between vaccine- and infection-derived 415 immunity, both for vaccine and serosurveillance studies.

416

417 Similarly, although the MVA-BN vaccine primarily induced antibodies specific to MVA 418 and VACV, there is a limited correlation between MVA and MPXV neutralising 419 antibodies³⁸. This suggests antigenic differences among Orthopoxviruses, an area 420 that should be investigated further to evaluate vaccine immunogenicity and cross-421 protection. Notably, this study only focused on Mpox Clade IIb, although it has been 422 observed there is no difference in antigen recognition between Clade IIa¹⁵, there are mutational differences observed between variants³⁹ which could lead to divergent 423 424 immune responses, an area to be explored further. Especially with the continued 425 spread of Clade I Mpox evidenced by recent outbreaks in the Democratic Republic of 426 Congo²⁹.

427

Analysis of antibody titres revealed distinct patterns across cohorts, providing essential information on the dynamics of the humoral immune response. Negative samples predominantly exhibited antibody titres below the cut-off values for all antigens, indicating either undetectable immune responses, or in those with low level reactivity being presumed cross-reactive antibodies and background noise. IMVANEX-vaccinated individuals post-dose one displayed an initial low, yet detectable and significantly higher (p=<0.00001) immune response against MPXV E8, M1, and

435 VACV A27, A33, D8 and L1 antigens compared to negatives (**Figure 2**). However, the 436 lack of antibody responses indicated here does not suggest lack of protection, with 437 IMVANEX vaccine efficacy after one dose assessed as $\geq 78\%^{11-14}$.

438

439 A significant increase in antibody titres is observed for MPXV A35 (p=0.021), B6 440 (p=0.026), E8 (p=0.022) and VACV B5 (p=0.042), L1 (p=0.022) in relation to PD1, 14-441 days from administration of the second dose (Figure 2), with VACV D8 (p=0.038) 442 demonstrating significant increases 43-days post second vaccination, suggesting a 443 necessity for a second dose, similarly observed in other (singleplex) assays^{15,16}. 444 Although it is shown antibodies are present, whether these antibodies provide 445 protection remains unanswered, emphasising the need for further investigation into 446 correlates of protection and antigen-specific responses on overall immunity.

447

448 Nevertheless, a subsequent decrease in antibody titres was observed ~84 days post-449 dose 2 (PD2.4, Figure 2), suggesting a waning of the humoral immune response to 450 MPXV and VACV antigens. A similar trend that we previously demonstrated with individual MPXV and VACV antigen ELISAs²⁸. The majority of samples remain above 451 452 the designated cut-off defined in this study up to 220 days post-dose two. After this, 453 median antibody titres decline for each antigen and are non-significantly different to 454 post dose one responses. MPXV A35 and B6 demonstrate the most pronounced 455 waning of immune responses post two doses of vaccination, specifically, antibody 456 titres wane to levels comparable to negative samples >185 days for MPXV A35 457 (PD2.7, Figure 2B) and >122 days for MPXV B6 (PD2.5, Figure 2C). The continued 458 waning of antigen-specific antibodies is being sought from ongoing longitudinal

investigations, using a panel of 12 MPXV-specific antigens, some of which can beassessed through this MSD assay.

461

462 Correlation between IMVANEX and Mpox-infected individuals against 463 MPXV/VACV homologous proteins

As previously shown¹⁵ when comparing antigen homologues IMVANEX vaccinated 464 465 sera showed preferential binding to VACV A33, B5 and D8 and MPXV convalescent 466 sera to MPXV A35, B6 and E8, respectively. MPXV A35 and VACV A33 had the most 467 pronounced differentiation (Figure 3) which corresponds to findings observed in other singleplex and multiplex ELISAs^{15,36}, highlighting that the type of antigen exposure 468 469 influences the subsequent antibody binding preference. All antigens within this assay 470 are MPXV and VACV homologous proteins, which could provide additional 471 mechanisms for differentiating between convalescent and vaccine-derived antibodies. 472 We observed that antibodies against MPXV A29 and VACV A27 were generally higher 473 in Mpox convalescent samples than those post-IMVANEX vaccination. MPXV A29 is highly conserved between MPXV and VACV⁴⁰ with a 93.6% sequence identity with 474 VACV A27 homologue,⁴¹ so the observation of a decreased humoral immune 475 476 response to MPXV A29 is not known and warrants further investigation. Instances of 477 truncated proteins (e.g., MPXV A27) have been observed in the MVA-BN strain, 478 suggesting something similar may have occurred which could aid further aid in the 479 differentiation between infected, historically vaccinated and recently vaccinated. 480 However, whilst there are reduced antibody titres, these antigens activate cellular 481 immunity and produce neutralising antibodies, providing a level of protection²¹. Further investigations into MPXV A29 and VACV A27 could provide a valuable insight into 482 483 immunity dynamics.

484 Conversely, with MPXV M1 and VACV L1 we observe antibody responses to these 485 antigens more evidently in those receiving the IMVANEX vaccine (Figure 2). MPXV M1 has been identified as an important immunogen⁴² and has 98.8% sequence 486 487 homology with VACV L1⁴¹, suggesting that the robust antibody response of M1 should 488 be mirrored in the homologous VACV protein. Due to the robust antibody and T-cell 489 responses with MPXV M1²⁷, this has been included in candidate multivalent mRNA 490 Orthopoxvirus vaccine along with MPXV A35, B6 and H3. We have similarly confirmed 491 the observation of M1 (and therefore L1) antibodies being vaccination specific¹⁵, 492 warranting further investigation as to the mechanism as to why these are vaccination 493 specific. Finally, using Pearson correlation we observed the relationship between 494 MPXV/VACV antigens. All antigens are significantly correlated to their corresponding 495 homologue, with MPXV E8/VACV D8 exhibiting the strongest correlation (Figure 4, 496 **Supplementary Table 3).** Additionally, we observed correlations between certain 497 antigens such as MPXV A35/VACV A33 correlated with MPXV B6/VACV B5, as well 498 as MPXV M1/VACV L1 correlated to VACV A33, MPXV E8/VACV D8, and MPXV B6/VACV B5. These correlations primarily involve immunodominant antigens^{15,21}, 499 500 suggesting their importance and the relationship between different antigens in the 501 overall immune response to infection and vaccination.

502 Conclusion

Here we demonstrate the MSD Orthopoxvirus assay is highly sensitive, specific, and reproducible for the detection of Orthopox-specific antibodies. This assay provides a valuable tool for serosurveillance and in the assessment of new generation Orthopox vaccine candidates as well as understanding Orthopoxvirus immunity. This assay provides benefits over current singleplex assays in its ability to test multiple antigens simultaneously, with opportunities for comprehensive studies and deeper insights into the ongoing spread of Mpox worldwide.


510 **References**

- 511 1. Shchelkunov, S. N. *et al. Human Monkeypox and Smallpox Viruses: Genomic* 512 *Comparison*. (2001).
- 513 2. Chen, N. *et al.* Virulence differences between monkeypox virus isolates from
 514 West Africa and the Congo basin. *Virology* **340**, 46–63 (2005).
- 515 3. Martín-Delgado, M. C. *et al.* Monkeypox in humans: a new outbreak. *Revista* 516 *Espanola de Quimioterapia* vol. 35 509–518 Preprint at 517 https://doi.org/10.37201/req/059.2022 (2022).
- 5184.Thornhill, J. P. *et al.* Monkeypox Virus Infection in Humans across 16 Countries519— April–June 2022. New England Journal of Medicine **387**, 679–691 (2022).
- 520 5. Isidro, J. *et al.* Phylogenomic characterization and signs of microevolution in the 521 2022 multi-country outbreak of monkeypox virus. *Nat Med* **28**, 1569–1572 522 (2022).
- 523 6. Lansiaux, E., Jain, N., Laivacuma, S. & Reinis, A. The virology of human 524 monkeypox virus (hMPXV): A brief overview. *Virus Res* **322**, (2022).
- 525 7. Petersen, E. *et al.* Human Monkeypox: Epidemiologic and Clinical 526 Characteristics, Diagnosis, and Prevention. *Infectious Disease Clinics of North* 527 *America* vol. 33 1027–1043 Preprint at https://doi.org/10.1016/j.idc.2019.03.001 528 (2019).
- 529 8. Weltzin, R. *et al.* Clonal vaccinia virus grown in cell culture as a new smallpox
 530 vaccine. *Nat Med* 9, 1125–1130 (2003).
- 5319.Fenner, F., Henderson, D. A., Arita, I., Ježek, Z. & Ladnyi, I. D. ,. 1987. Smallpox532and its eradication. Geneva: WHO, p.210. Geneva: WHO, p.210. 210 (1987).
- Petersen, B. W., Harms, T. J., Reynolds, M. G. & Harrison, L. H. Use of Vaccinia
 Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for
 Occupational Exposure to Orthopoxviruses Recommendations of the
 Advisory Committee on Immunization Practices (ACIP), 2015. *MMWR Morb Mortal Wkly Rep* 65, 257–262 (2016).
- 538 11. Bertran, M. *et al.* Effectiveness of one dose of MVA–BN smallpox vaccine
 539 against mpox in England using the case-coverage method: an observational
 540 study. *Lancet Infect Dis* 23, 828–835 (2023).
- 541 12. Saadh, M. J. *et al.* Progress and prospects on vaccine development against
 542 monkeypox infection. *Microbial Pathogenesis* vol. 180 Preprint at
 543 https://doi.org/10.1016/j.micpath.2023.106156 (2023).
- 54413.Gong, Q., Wang, C., Chuai, X. & Chiu, S. Monkeypox virus: a re-emergent threat545to humans.VirologicaSinicavol.37477–482Preprintat546https://doi.org/10.1016/j.virs.2022.07.006 (2022).
- 547 14. Dalton, A. F. et al. Estimated Effectiveness of JYNNEOS Vaccine in Preventing:
 548 A Multijurisdictional Case-Control Study United, August 19, 2022–March 31,
 549 2023. (2023).

- 550 15. Otter, A. D. *et al.* Monkeypox virus-infected individuals mount comparable
 551 humoral immune responses as Smallpox-vaccinated individuals. *Nat Commun*552 14, (2023).
- 16. Cohn, H. *et al.* Mpox vaccine and infection-driven human immune signatures:
 an immunological analysis of an observational study. *Lancet Infect Dis* 23, 1302–1312 (2023).
- Ahmed, S. F., Sohail, M. S., Quadeer, A. A. & McKay, M. R. Vaccinia-VirusBased Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the
 2022 Monkeypox Virus. *Viruses* 14, (2022).
- Laliberte, J. P., Weisberg, A. S. & Moss, B. The membrane fusion step of
 vaccinia virus entry is cooperatively mediated by multiple viral proteins and host
 cell components. *PLoS Pathog* 7, (2011).
- 562 19. Bengali, Z., Satheshkumar, P. S. & Moss, B. Orthopoxvirus species and strain 563 differences in cell entry. *Virology* **433**, 506–512 (2012).
- 564 20. Yates, J. L. *et al.* Development of a novel serological assay for the detection of 565 mpox infection in vaccinated populations. *J Med Virol* **95**, (2023).
- Yang, X. *et al.* A Subunit Vaccine Candidate Composed of Mpox Virus A29L,
 M1R, A35R, and B6R Elicits Robust Immune Response in Mice. *Vaccines*(*Basel*) 11, (2023).
- Berhanu, A. *et al.* Vaccination of BALB/c Mice with Escherichia coli -Expressed
 Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia
 Virus Challenge . *J Virol* 82, 3517–3529 (2008).
- 572 23. Lee, W., Kim, Y. J., Lee, S. J., Ahn, D. G. & Kim, S. J. Current Status of
 573 Epidemiology, Diagnosis, Therapeutics, and Vaccines for the Re-Emerging
 574 Human Monkeypox Virus. *J Microbiol Biotechnol* 33, 981–991 (2023).
- 575 24. Shi, D. *et al.* Kinetic and Structural Aspects of Glycosaminoglycan–Monkeypox
 576 Virus Protein A29 Interactions Using Surface Plasmon Resonance. *Molecules*577 27, (2022).
- 578 25. Roberts, K. L. *et al.* Acidic residues in the membrane-proximal stalk region of 579 vaccinia virus protein B5 are required for glycosaminoglycan-mediated 580 disruption of the extracellular enveloped virus outer membrane. *Journal of* 581 *General Virology* **90**, 1582–1591 (2009).
- 582 26. Bell, E. *et al.* Antibodies against the extracellular enveloped virus B5R protein 583 are mainly responsible for the EEV neutralizing capacity of vaccinia immune 584 globulin. *Virology* **325**, 425–431 (2004).
- 585 27. Zuiani, A. *et al.* A multivalent mRNA monkeypox virus vaccine (BNT166)
 586 protects mice and macaques from orthopoxvirus disease. *Cell* (2024)
 587 doi:10.1016/j.cell.2024.01.017.
- 58828.Otter, A. D. *et al.* Analogous humoral antigen recognition between Monkeypox-589infected and Smallpox-vaccinated individuals.(2022)590doi:10.1101/2022.12.22.2283648.
- 59129.Angel N. Desai *et al.* Implications of the 2023-2024 MPXV Clade I Outbreak in592the DRC to Global Public Health. *Clinical Microbiology and Infection* (2024).

- 593 30. Tang, D. *et al.* Recombinant proteins A29L, M1R, A35R, and B6R vaccination 594 protects mice from mpox virus challenge. *Front Immunol* **14**, (2023).
- 595 31. Davies, D. H. *et al.* Antibody Profiling by Proteome Microarray Reveals the
 596 Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus
 597 Ankara Is Comparable to That of Dryvax. *J Virol* 82, 652–663 (2008).
- 598 32. Pütz, M. M., Midgley, C. M., Law, M. & Smith, G. L. Quantification of antibody 599 responses against multiple antigens of the two infectious forms of Vaccinia virus 600 provides a benchmark for smallpox vaccination. *Nat Med* **12**, 1310–1315 (2006).
- 601 33. Hou, F. *et al.* mRNA vaccines encoding fusion proteins of monkeypox virus 602 antigens protect mice from vaccinia virus challenge. *Nat Commun* **14**, (2023).
- Shi, D. *et al.* Kinetic and Structural Aspects of Glycosaminoglycan–Monkeypox
 Virus Protein A29 Interactions Using Surface Plasmon Resonance. *Molecules* **27**, (2022).
- Grifoni, A. *et al.* Defining antigen targets to dissect vaccinia virus and
 monkeypox virus-specific T cell responses in humans. *Cell Host Microbe* 30,
 1662-1670.e4 (2022).
- 36. Jones, S. et al. MpoxPlex: a high-throughput and versatile multiplexed
 immunoassay for assessing and discriminating between IgG responses to Mpox
 infection and vaccination. *MedRxiv* (2024).
- 612 37. Freyn, A. W. et al. An Mpox Virus MRNA-Lipid Nanoparticle Vaccine Confers
 613 Protection against Lethal Orthopoxviral Challenge. https://www.science.org
 614 (2023).
- 38. Zaeck, L. M. *et al.* Low levels of monkeypox virus-neutralizing antibodies after
 MVA-BN vaccination in healthy individuals. *Nat Med* 29, 270–278 (2023).
- 61739.Gigante, C. M. et al. Multiple Lineages of Monkeypox Virus Detected in the618United States, 2021-2022. https://www.science.org (2022).
- 619 40. Gao, F. *et al.* Cross-reactive immune responses to monkeypox virus induced by
 620 MVA vaccination in mice. *Virol J* 20, (2023).
- 41. Shchelkunov, S. N. *et al.* Analysis of the monkeypox virus genome. *Virology*297, 172–194 (2002).
- 42. Bisht, H., Weisberg, A. S. & Moss, B. Vaccinia Virus L1 Protein Is Required for
 Cell Entry and Membrane Fusion. *J Virol* 82, 8687–8694 (2008).
- 625

627 Supplementary Material



628

629 Figure 1: Receiver Operating Curves (ROC) for MPXV (black) and VACV (blue)

homologous proteins. Evaluating the sensitivity and specificity of homologues with
negative (n=215) versus Mpox-infected (n=39) and IMVANEX vaccinated (n=80)
individuals. A) MPXV A29 & VAC A27, B) MPXV A35 & VACV A33, C) MPXV B6 &
VACV B5, D) MPXV E8 & D8 and E) MPXV M1 & VACV L. Each solid line represents
the ROC for individual antigens, while the dashed red line is a random classifier.






Figure 2: Combined antigen ROC curves. A) Comparing negative versus either (i.)
Mpox-infected & IMVANEX infected, (ii.) Mpox-infected or (iii.) IMVANEX vaccinated.
Evaluating antigen positivity across a spectrum of one to ten antigens relative to cutoff values detailed in Table 1. B) ROC curve for all ten antigens based on positivity
scores, for IMVANEX vaccinated, Mpox-infected and both combined.

Table 1: Summary of ROC curves and individual antigen cut offs. A) Mpox-infected and **B)** IMVANEX vaccinated. Cut-offs were 646 generated but comparing all positive samples (either Mpox-infected (n=39) or IMVANEX vaccinated (n=80) with all negative samples

647 to each MPXV/VACV antigen by ROC analysis.

Antigen	Cut off	Sensitivity %	95% CI	Specificity %	95% CI	Likelihood Ratio	AUC			
A) Mpox-Infected										
MPXV A29L (NEGS Vs MPXV)	> 6.976	88.89	74.69% to 95.59%	90.09	85.45% to 93.36%	8.97	0.938			
MPXV A35R (NEGS Vs MPXV)	> 37.09	94.29	81.39% to 98.98%	99.11	96.80% to 99.84%	105.61	0.981			
MPXV B6R (NEGS Vs MPXV)	> 6.706	94.59	82.30% to 99.04%	97.31	94.26% to 98.76%	35.16	0.986			
MPXV E8L (NEGS Vs MPXV)	> 23.83	94.44	74.24% to 99.72%	95.98	92.54% to 97.87%	23.51	0.975			
MPXV M1R (NEGS Vs MPXV)	> 6.852	81.58	66.58% to 90.78%	77.23	71.31% to 82.24%	3.58	0.856			
VACV A27L (NEGS Vs MPXV)	> 5.014	88.89	74.69% to 95.59%	84.32	78.39% to 88.86%	5.67	0.923			
VACV A33R (NEGS Vs MPXV)	> 9.251	89.47	75.87% to 95.83%	96.88	93.69% to 98.48%	28.63	0.989			
VACV B5R (NEGS Vs MPXV)	> 8.307	94.59	82.30% to 99.04%	96.41	93.08% to 98.17%	26.37	0.982			
VACV D8L (NEGS Vs MPXV)	> 11.84	93.55	79.28% to 98.85%	95.54	91.98% to 97.56%	20.95	0.974			
		В)	IMVANEX Vaccinated							
MPXV A29L (NEGS Vs IMVANEX)	> 0.9492	57.69	46.62% to 68.04%	69.82	63.49% to 75.48%	1.91	0.6756			
MPXV A35R (NEGS Vs IMVANEX)	> 2.752	89.19	80.09% to 94.42%	90.63	86.09% to 93.79%	9.51	0.9601			
MPXV B6R (NEGS Vs IMVANEX)	> 1.112	97.18	90.30% to 99.50%	91.93	87.60% to 94.83%	12.04	0.9887			
MPXV E8L (NEGS Vs IMVANEX)	> 22.20	100	92.29% to 100.0%	95.98	92.54% to 97.87%	24.89	0.9943			
MPXV M1R (NEGS Vs IMVANEX)	> 11.19	91.3	82.30% to 95.95%	84.82	79.54% to 88.93%	6.02	0.9391			
VACV A27L (NEGS Vs IMVANEX)	> 2.112	46.38	35.11% to 58.02%	75.68	69.01% to 81.29%	1.91	0.6413			
VACV A33R (NEGS Vs IMVANEX)	> 6.349	94.37	86.39% to 97.79%	95.54	91.98% to 97.56%	21.14	0.9865			
VACV B5R (NEGS Vs IMVANEX)	> 6.151	95.65	87.98% to 98.81%	95.52	91.94% to 97.55%	21.33	0.9885			
VACV D8L (NEGS Vs IMVANEX)	> 48.38	100	90.11% to 100.0%	98.66	96.14% to 99.63%	74.67	0.9968			
VACV L1R (NEGS Vs IMVANEX)	> 10.37	92.96	84.55% to 96.95%	83.93	78.55% to 88.16%	5.78	0.9545			

Table 2: Median antibody concentrations (AU/ml) for all MPXV and VACV antigens. For paediatric negatives (n=215), 24 days post-dose one (PD1), 14 days post-dose two (PD2.1), with following longitudinal timepoints: 43 days (PD2.2), 43 days (PD2.2), 63 days (PD2.3), 84 days (PD2.4), 122 days (PD2.5), 157 days (PD2.6), 185 days (PD2.7), 220 days (PD2.8) and Mpox-infected (n=39). The corresponding cut-off for each antigen was assigned using ROC analysis. Cells highlighted in green show the median concentrations to be above the assigned cut-off.

Median Antibody Concentration (AU/mI)													
Antigen	Species	Paediatric Negative	PD1	PD2.1	PD2.2	PD2.3	PD2.4	PD2.5	PD2.6	PD2.7	PD2.8	MPXV22	Cut off
A29L	MPXV	0.3457	4.8	2.0	3.65	1.6	1.5	0.684	0.248	0.314	1.108	96.07	2.36
A27L	VACV	0.5878	5.8	4.3	5.7	2.8	2.7	0.865	0.357	0.327	2.59	64.52	2.11
A35R	MPXV	0.07092	7.0	736.8	216.1	101.2	145	48.18	5.073	5.093	12.77	2281	2.75
A33R	VACV	0.05385	14.5	1931	580.1	421.5	744.6	244	20.21	53.66	43.91	183.5	6.35
B6R	MPXV	0.03213	8.3	5523	1548	238.3	428.3	202.8	30.94	21.03	42.88	1617	2.67
B5R	VACV	0.1093	23.6	3052	2764	1024	864.6	656.4	83.78	295.6	485.2	1398	6.15
E8L	MPXV	0.3137	505.2	6787	9534	731	3370	1983	3229	3156	1491	2370	22.20
D8L	VACV	0.2977	5332	13100	14582	1916	752.1	3432	8200	5446	2401	1459	25.99
M1R	MPXV	2.264	80.0	1408	1021	221.3	186.1	71.74	110.8	86.58	156.3	24.64	11.19
L1R	VACV	1.94	121.7	908.4	780	114.6	439.2	204.6	167.3	91.41	195.6	19.57	10.37

Green = above cut-off

662 Supplementary Table 3: Correlation between MPXV/VACV antigens using Pearson r. Significant values (p≤0.05) are indicated

663 with corresponding p values.

664

	MPXV A29L	VACV A27L	MPXV A35R	VACV A33R	MPXV B6R	VACV B5R	MPXV E8L	VACV D8L	MPXV M1R	VACV L1R
MPXV A29L	1.000	0.393 (p=2.13E-05)	0.026	-0.047	0.036	0.161	0.019	-0.041	0.145	0.103
VACV A27L	0.393 (p=2.13E-05)	1.000	-0.079	-0.096	-0.094	-0.044	-0.145	-0.115	-0.038	-0.046
MPXV A35R	0.026	-0.079	1.000	0.329 (p=0.0005)	0.346 (<i>p=0.0003</i>)	0.397 (p=3.25E-05)	0.044	-0.110	-0.130	-0.094
VACV A33R	-0.047	-0.096	0.329 (p=0.0005)	1.000	0.568 (p=1.00E-10)	0.569 (p=1.93E-10)	0.148	0.086	0.033	0.232 (p=0.0157)
MPXV B6R	0.036	-0.094	0.346 (p=0.0003)	0.568 (p=1.00E-10)	1.000	0.734 (p=3.76E-19)	0.191	0.018	0.195 (<i>p=0.0457</i>)	0.353 (p=0.0002)
VACV B5R	0.161	-0.044	0.397 (p=3.25E-05)	0.569 (p=1.93E-10)	0.734 (p=3.76E-19)	1.000	0.223 (p=0.0370)	0.103	0.387 (p=5.48E-05)	0.474 (p=3.37E-07)
MPXV E8L	0.019	-0.145	0.044	0.148	0.191	0.223 (p=0.0370)	1.000	0.94 (p=7.37E-43)	0.531 (p=1.22E-07)	0.339 (p=0.0012)
VACV D8L	-0.041	-0.115	-0.110	0.086	0.018	0.103	0.94 (p=7.37E-43)	1.000	0.481 (p=1.79E-06)	0.278 (p=0.0080)
MPXV M1R	0.145	-0.038	-0.130	0.033	0.195 (<i>p=0.0457</i>)	0.387 (p=5.48E-05)	0.531 (p=1.22E-07)	0.481 (p=1.79E-06)	1.000	0.914 (p=6.85E-43)
VACV L1R	0.103	-0.046	-0.094	0.232 (p=0.0157)	0.353 (p=0.0002)	0.474 (p=3.37E-07)	0.339 (p=0.0012)	0.278 (p=0.0080)	0.914 (p=6.85E-43)	1.000